Kegg Pathway: Toll-like receptor signaling pathway

KEGG ID: 04620

Reference Diagram

KEGG Diagram for Toll-like receptor signaling pathway

Rat

There are 86 IPI Records from this pathway found in Rattus norvegicus.

Location of Toll-like receptor signaling pathway proteins on Rat Genome

IPI Record Position
1: Akt1 6:137640482-137657552
2: Akt2 1:82686233-82726544
3: Akt3 13:92807672-92924984
4: Casp8 9:57389353-57437803
5: Ccl3 10:71744559-71746109
6: Ccl5 10:71605827-71610342
7: Cd14 18:29374597-29376328
8: Cd80 11:64045341-64070083
9: Cd86 11:66215233-66238882
10: Chuk_predicted 1:249122847-249157179
11: Cxcl10 14:17265986-17268183
12: Cxcl11 14:17250648-17253423
13: Fadd 1:205009564-205012786
14: Fos 6:109559154-109562546
15: Ifna1 5:108011739-108012317
16: Ifna11_predicted 5:108150128-108150703
17: Ifna2_predicted 5:108085633-108118114
18: Ifnar1_predicted 11:31455064-31479849
19: Ifnb1 5:107837628-107838182
20: Ikbkb 16:73805082-73858088
21: Ikbke_predicted 13:44197626-44219753
22: Ikbkg X:160407166-160420190
23: Il12a 2:158710261-158717689
24: Il12b 10:29558955-29567748
25: Il1b 3:116964427-116970887
26: Il6 4:456799-461376
27: IPI00190306 7:127444268-127449919
28: IPI00366392 7:60863797-60893714
29: IPI00766451 :-
30: Irak1_predicted X:159959294-159969180
31: Irak4_predicted 7:133054573-133081527
32: Irf5_predicted 4:56407596-56418693
33: Irf7 1:201456689-201459756
34: Jun 5:115359397-115360401
35: Lbp 3:149016588-149044084
36: LOC684440 :-
37: Ly96 5:1701972-1705258
38: Map2k1 8:68379077-68451583
39: Map2k2 7:10074654-10094005
40: Map2k3 10:47075216-47096628
41: Map2k4 10:52008647-52041626
42: Map2k6 10:99859584-99974643
43: Map2k7 12:1543467-1552353
44: Map3k7ip2 1:2568080-2617709
45: Map3k7_predicted 5:48252637-48308832
46: Map3k8 17:61910179-61930459
47: Mapk1 11:85968732-86030389
48: Mapk10 14:7865731-8010694
49: Mapk12 7:127430616-127441308
50: Mapk13 20:7055371-7064156
51: Mapk14 20:6939249-7000378
52: Mapk3 1:185935044-185941249
53: Mapk8 16:8925133-8954535
54: Mapk9 10:35344672-35384319
55: Myd88 8:124299725-124303798
56: Nfkb1 2:233091020-233187501
57: Nfkb2 1:251521559-251527815
58: Nfkbia 6:75729302-75732474
59: Pik3ca 2:118640277-118670170
60: Pik3cb 8:103886682-103957112
61: Pik3cd_predicted 5:166735338-166750186
62: Pik3cg_predicted 6:50444793-50477111
63: Pik3r1 2:32602673-32675350
64: Pik3r2 16:19171101-19179650
65: Pik3r3 5:136497494-136566473
66: Rac1 12:11380314-11400531
67: Rela 1:208263316-208272419
68: RGD1559932_predicted :-
69: RGD1563261_predicted 10:55182226-55247889
70: RGD1565911_predicted :-
71: Ripk1_predicted 17:37185782-37211023
72: Spp1 :-
73: Stat1 9:46460407-46650076
74: Ticam2_predicted :-
75: Tlr2 2:175607990-175613992
76: Tlr3 16:50112910-50126371
77: Tlr4 5:83564096-83577731
78: Tlr5 13:99017796-99029047
79: Tlr6 14:46098184-46100686
80: Tlr7_predicted X:47353533-47356682
81: Tlr9 :-
82: Tnf 20:3661000-3663618
83: Tnfrsf5 3:156092602-156107432
84: Tollip_predicted 1:201997982-202029669
85: Traf3_predicted 6:135997472-136022606
86: Traf6_predicted 3:86831738-86846484

Mouse

There are 86 IPI Records from this pathway found in Mus musculus.

Location of Toll-like receptor signaling pathway proteins on Mouse Genome

IPI Record Position
1: Akt1 :-
2: Akt2 7:27300516-27348213
3: Akt3 1:178862039-178967772
4: Casp8 1:58739978-58791553
5: Ccl3 11:83464040-83465552
6: Ccl4 11:83478782-83480875
7: Ccl5 11:83341978-83346713
8: Cd14 18:36851038-36852628
9: Cd40 2:164746841-164762859
10: Cd80 16:38378357-38405776
11: Cd86 16:36523108-36585290
12: Chuk 19:44126647-44160756
13: Cxcl9 5:93398190-93403317
14: Fadd 7:144387713-144391826
15: Fos 12:86363004-86366372
16: Ifna1 4:88321318-88321887
17: Ifna11 4:88291124-88292606
18: Ifna13 4:88115047-88115616
19: Ifna2 4:88154438-88155010
20: Ifna4 4:88313092-88313652
21: Ifna5 4:88306756-88307325
22: Ifna6 :-
23: Ifna7 4:88287459-88288031
24: Ifna9 4:88063037-88074607
25: Ifnab 4:88161886-88162458
26: Ifnar1 16:91374108-91396296
27: Ifnar2 16:91261758-91294444
28: Ifnb1 4:87993457-87994005
29: Ikbkb 8:24124758-24172108
30: Ikbke 1:133082148-133107109
31: Ikbkg X:70677332-70704240
32: Il12a 3:68778573-68786454
33: Il12b 11:44243486-44257456
34: Il1b 2:129056011-129062561
35: Il6 5:30343948-30350755
36: Irak1 X:70266646-70276641
37: Irak4 15:94371840-94396486
38: Irf3 7:44865702-44870890
39: Irf5 6:29476743-29487329
40: Irf7 7:141114504-141117743
41: Jun 4:94542255-94544189
42: Lbp 2:157997986-158023737
43: Ly96 1:16673647-16694819
44: Map2k1 9:63983787-64051430
45: Map2k2 10:80509092-80527465
46: Map2k3 11:60748250-60769002
47: Map2k4 11:65504439-65604492
48: Map2k6 11:110215212-110341612
49: Map2k7 8:4238828-4251420
50: Map3k7 4:32292729-32349408
51: Map3k7ip1 15:79960409-79988964
52: Map3k7ip2 10:7596309-7615052
53: Map3k8 18:4331325-4352951
54: Mapk1 16:16896945-16961016
55: Mapk10 5:103148770-103149081
56: Mapk11 15:88970253-88977372
57: Mapk12 15:88958350-88968387
58: Mapk13 17:28496937-28506286
59: Mapk14 17:28418955-28475994
60: Mapk3 7:126550780-126556964
61: Mapk8 14:32209888-32276220
62: Mapk9 11:49690177-49729834
63: Myd88 9:119184642-119188700
64: Nfkb1 3:135292997-135605172
65: Nfkb2 19:46358111-46365401
66: Nfkbia 12:56407731-56410725
67: Pik3ca 3:32627755-32654380
68: Pik3cb 9:98847754-98949439
69: Pik3cd 4:148492970-148542498
70: Pik3cg 12:32758720-32793858
71: Pik3r1 13:102781018-102868441
72: Pik3r2 8:73697168-73705691
73: Pik3r3 4:115719846-115800988
74: Pik3r5 11:68248320-68314041
75: Q80SS5_MOUSE 4:88063037-88074607
76: Q810G3_MOUSE 4:88028904-88043029
77: Rac1 5:143761100-143783654
78: Rela 19:5637490-5648130
79: Ripk1 13:34010339-34042635
80: Spp1 5:104675436-104681350
81: Stat1 1:52064035-52066799
82: Tbk1 10:120949520-120989807
83: Ticam1 17:55903179-55910466
84: Ticam2 18:46683562-46699863
85: Tirap 9:34938328-34940755
86: Tlr1 5:65203969-65211834
87: Tlr2 3:83922197-83927694
88: Tlr3 8:46894482-46909356
89: Tlr4 4:66313972-66328954
90: Tlr5 :-
91: Tlr6 5:65232241-65239170
92: Tlr7 X:162649036-162674633
93: Tlr8 X:162586799-162607911
94: Tlr9 9:106081616-106084711
95: Tnf 17:34807442-34810048
96: Tollip 7:141684203-141711805
97: Traf3 12:111614356-111714956
98: Traf6 2:101479279-101501817

Human

There are 86 IPI Records from this pathway found in Homo sapiens.

Location of Toll-like receptor signaling pathway proteins on Human Genome

IPI Record Position
1: AKT1 14:104306734-104333125
2: AKT2 19:45430084-45483036
3: AKT3 1:241718158-242080053
4: CASP8 2:201806426-201860677
5: CCL3 17:31439737-31441517
6: CCL4 17:31455333-31457127
7: CCL5 17:31222613-31231490
8: CD14 5:139991522-139993157
9: CD40 20:44180318-44366257
10: CD80 3:120725835-120761139
11: CD86 3:123256911-123322672
12: CXCL10 4:77161297-77163674
13: CXCL11 4:77173975-77176376
14: CXCL9 4:77141523-77147648
15: FADD 11:69726917-69731134
16: FOS 14:74815284-74818685
17: IFNA10 9:21196180-21197142
18: IFNA13 9:21430440-21431315
19: IFNA14 9:21191234-21229990
20: IFNA16 9:21206372-21207310
21: IFNA17 9:21217242-21218221
22: IFNA2 9:21374253-21375387
23: IFNA21 9:21155636-21156659
24: IFNA4 9:21176693-21177670
25: IFNA5 9:21294325-21295311
26: IFNA6 9:21339834-21341377
27: IFNA7 9:21191234-21229990
28: IFNA8 9:21399146-21400184
29: IFNAR1 21:33619079-33654038
30: IFNAR2 21:33524076-33559839
31: IFNB1 9:21067104-21067962
32: IKBKB 8:42247986-42309130
33: IKBKE 1:204710414-204736846
34: IKBKG X:153423653-153446455
35: IL12A 3:161189323-161196499
36: IL12B 5:158674369-158690059
37: IL1B 2:113303808-113310827
38: IL6 7:22732028-22738091
39: IL8 4:74825139-74828295
40: IRAK1 X:152929145-152938625
41: IRAK4 12:42439067-42468164
42: IRF3 19:54854642-54860926
43: IRF5 7:128365230-128377320
44: IRF7 11:602591-605936
45: JUN 1:59019048-59022587
46: LBP 20:36408299-36439067
47: LY96 8:75066141-75103859
48: MAP2K1 15:64466674-64570935
49: MAP2K2 19:4041331-4075126
50: MAP2K3 17:21128626-21159118
51: MAP2K4 17:11864866-11987865
52: MAP2K6 17:64922434-65051067
53: MAP2K7 19:7874728-7885362
54: MAP3K7 6:91280013-91353485
55: MAP3K7IP1 22:38125692-38163078
56: MAP3K7IP2 6:149680756-149774442
57: MAP3K8 10:30762872-30790768
58: MAPK1 22:20446873-20551730
59: MAPK10 4:87156656-87511051
60: MAPK11 22:49044295-49050949
61: MAPK12 22:49033484-49042312
62: MAPK13 6:36129769-36215820
63: MAPK14 6:36103551-36186513
64: MAPK3 16:30032951-30042116
65: MAPK8 10:49184739-49317409
66: MAPK9 5:179595388-179640218
67: MYD88 3:38155157-38159514
68: NFKB1 4:103641518-103757506
69: NFKB2 10:104144320-104152271
70: NFKBIA 14:34940475-34943703
71: PIK3CA 3:180349005-180435189
72: PIK3CB 3:139856921-139960875
73: PIK3CD 1:9634390-9711564
74: PIK3CG 7:106292977-106334801
75: PIK3R1 5:67547360-67633403
76: PIK3R2 19:18125016-18142343
77: PIK3R3 1:46278399-46371054
78: PIK3R5 17:8722953-8756559
79: RAC1 7:6380651-6410120
80: RELA 11:65177649-65186959
81: RIPK1 6:3009212-3060418
82: SPP1 4:89115890-89123592
83: STAT1 2:191542121-191587181
84: TBK1 12:63132167-63182153
85: TICAM1 19:4766944-4782716
86: TIRAP 11:125658212-125672683
87: TLR1 4:38474275-38482807
88: TLR2 4:154842102-154846301
89: TLR3 4:187227303-187243244
90: TLR4 9:119506471-119518970
91: TLR5 1:221350270-221383247
92: TLR6 4:38504618-38507555
93: TLR7 X:12795123-12818420
94: TLR8 X:12834679-12851205
95: TLR9 3:52230138-52235219
96: TNF 6:31678016-31680778
97: TOLLIP 11:1252178-1287425
98: TRAF3 14:102406268-102441895
99: TRAF6 11:36467299-36488398

Google Scholar

Recent Literature

Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.

Inflamm Bowel Dis. 2009 Nov 18;
Pasternak BA, D'Mello S, Jurickova II, Han X, Willson T, Flick L, Petiniot L, Uozumi N, Divanovic S, Traurnicht A, Bonkowski E, Kugathasan S, Karp CL, Denson LA

BACKGROUND:: Systemic exposure to lipopolysaccharide (LPS) has been linked to clinical disease activity in adults with inflammatory bowel disease (IBD). We hypothesized that markers of LPS exposure and the acute phase response (APR) would be increased in pediatric IBD patients with growth failure, and that LPS signaling would be required for induction of the APR in murine colitis. METHODS:: Serum markers of LPS exposure, endotoxin core IgA antibody (EndoCAb), and the APR, LPS binding protein (LBP) were quantified in pediatric IBD patients and controls. LBP and cytokine production were determined after administration of trinitrobenzene sulfonic acid (TNBS) enemas to mice with genetic deletion of Toll-like receptor 4 (TLR4), and wildtype (WT) controls. RESULTS:: Serum EndoCAb and LBP were significantly elevated in patients with Crohn's disease (CD), compared to disease controls with ulcerative colitis (UC) and healthy controls (P < 0.001). This was independent of disease activity or location. CD patients with elevated serum EndoCAb and LBP exhibited linear growth failure which persisted during therapy. Serum LBP increased in WT mice following TNBS administration, in conjunction with increased serum TNF-alpha, IL-6, and IL-10, and expansion of regulatory T-cell numbers. Both the APR and expansion of foxp3+ T cells were abrogated in TLR4-deficient mice, in conjunction with a reduction in acute weight loss. CONCLUSIONS:: LPS exposure and a persistent APR are associated with growth failure in pediatric CD. LPS signaling is required for the APR in murine colitis. Therapies targeting this pathway may benefit the subset of patients with refractory growth failure. (Inflamm Bowel Dis 2010).

Helminth cysteine proteases inhibit TRIF-dependent activation of macrophages via degradation of TLR3.

J Biol Chem. 2009 Nov 18;
Donnelly S, O'Neill SM, Stack CM, Robinson MW, Turnbull L, Whitchurch C, Dalton JP

Helminth pathogens prepare a Th2 type immunological environment in their hosts to ensure their longevity. They achieve this by secreting molecules that not only actively drive type 2 responses but also suppress type 1 responses. Here, we show that the major cysteine proteases secreted from the helminth pathogens F. hepatica (FheCL1) and S. mansoni (SmCB1) protect mice from the lethal effects of lipopolysaccharide (LPS) by preventing the release of inflammatory mediators, nitric oxide, IL-6, TNFalpha and IL-12, from macrophages. The proteases specifically block the MyD88-independent TRIF-dependent signaling pathway of TLR-4 and TLR-3. Microscopical and flow-cytometric studies, however, show that alteration of macrophage function by cysteine protease is not mediated by cleavage of components of the Toll-like receptor 4 (TLR4) complex on the cell surface but occurs by degradation of TLR3 within the endosome. This is the first study to describe a parasite molecule that degrades this receptor and pinpoints a novel mechanism by which helminth parasites modulate the innate immune responses of their hosts to suppress the development of Th1 responses.

Immunostimulatory Bioactivity of Algal Polysaccharides from Chlorella pyrenoidosa Activates Macrophages via Toll-like receptor 4.

J Agric Food Chem. 2009 Nov 16;
Hsu HY, Jeyashoke N, Yeh CH, Song YJ, Hua KF, Chao LK

Much research suggests that a dietary supplement of Chlorella pyrenoidosa may be helpful to human health, but the molecular mechanism involved remains unclear. The aim of this research was to investigate the effects of certain hot-water-soluble polysaccharides from Chlorella pyrenoidosa (CWSP) on cytokine production, human leukocyte antigen (HLA) expression, and costimulatory molecule expression in macrophages. We demonstrated that CWSP induced IL-1beta secretion in macrophages via Toll-like receptor 4 (TLR4) mediated protein kinase signaling pathways. In addition, CWSP also stimulated the cell surface expression of HLA-DA, -DB, and -DC, and HLA-DR, -DP, and -DQ as well as the expression of costimulatory family molecules such as CD80 and CD86 in macrophages. Furthermore, we demonstrated that preinjection of C57BL/6J mice with CWSP increased lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha and IL-1beta secretion into serum in vivo. This outcome was consistent with the corresponding outcome for cells treated with CWSP in vitro. Our current results provide support for the possible use of CWSP as a modulation agent of immune responses in humans and certain animal species. Finally, in using GC-MS to analyze the polysaccharides, we found that the major monosaccharides of CWSP were rhamnose (31.8%), glucose (20.42%), galactose (10.28%), mannose (5.23%), and xylose (1.27%). This study is the first to report the molecular mechanism of immune-modulated signal transduction in vitro from the polysaccharides of Chlorella pyrenoidosa.

Toll-like receptor initiated host defense against Toxoplasma gondii.

J Biomed Biotechnol. 2010; 2010: 737125
Denkers EY

Toxoplasma gondii is an intracellular pathogen notable for its ability to establish a stable host-parasite relationship amongst a wide range of host species and in a large percentage of the human population. Toll-like receptor signaling through MyD88 is a critical pathway in initiating defense against this opportunistic protozoan and may also be a mediator of pathology during immune dysfunction. Other MyD88 independent signaling pathways are also involved in the host-parasite interaction. These responses can be triggered by the parasite itself, but interactions with the intestinal microbiota add additional complexity during enteric infection.

MyD88-dependent and -independent activation of TREM-1 via specific TLR ligands.

Eur J Immunol. 2009 Nov 10;
Heng Z, Heiderscheidt CA, Joo M, Gao X, Knezevic N, Mehta D, Sadikot RT

Triggering receptor expressed on myeloid cells (TREM)-1 plays an important role in myeloid cell-activated inflammatory responses. Although TLR ligands such as LPS and LTA have been shown to upregulate TREM-1 expression in macrophage and neutrophils the role of specific Toll like receptors in inducing the expression of TREM-1 remains unclear. In this study we investigated whether the presence of TLRs is necessary for the expression of TREM-1. We show that bone marrow derived macrophages from TLR4 and TLR2 knockout mice failed to induce expression of TREM-1 message and protein in response to their specific ligands. Intriguingly, the expression of TREM-1 in response to LPS is not altered in MyD88 knockout macrophages suggesting that downstream of Toll receptors a MyD88-independent pathway induces the expression of TREM-1. Inhibiting TRIF expression by siRNA decreased TREM-1 expression in response to LPS suggesting that the expression of TREM-1 in response to LPS was mediated by the TRIF signaling pathway. On the other hand the expression of TREM-1 in response to LTA is dependent on MyD88 expression. These data indicate that the expression of TREM-1 in response to TLR ligands occurs secondary to downstream signaling events and that presence of TLRs is necessary for the expression of TREM-1 in response to their specific ligands. However the downstream signaling required for the expression of TREM-1 is dependent on the stimulus and the surface receptor through which the signaling is initiated.

A novel Toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.

Clin Cancer Res. 2009 Nov 15; 15(22): 6921-30
Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G

PURPOSE: Resistance to anti-HER2 monoclonal antibody trastuzumab is a relevant issue in breast cancer patients. Among the mechanisms implicated in trastuzumab resistance, increasing evidence supports a role of tumor microenvironment. We previously found that a novel Toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, acts through epidermal growth factor receptor (EGFR) and shows direct antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF drugs, thus interfering with cancer cells and microenvironment. EXPERIMENTAL DESIGN: In this study, we used KPL-4 and JIMT-1 trastuzumab-resistant breast cancer cells to evaluate the combination IMO plus trastuzumab as a therapeutic option for trastuzumab-resistant breast cancers. RESULTS: IMO inhibits KPL-4 and JIMT-1 xenografts growth and potentiates trastuzumab antitumor effect, with complete suppression of tumor growth, potent enhancement of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity, and strong inhibition of EGFR/HER2-related signaling. In KPL-4 xenografts, IMO alone interferes with HER signal transduction, whereas trastuzumab is ineffective. IMO induces an HER-dependent signal inhibition also in vitro by modulating a functional interaction between Toll-like receptor 9 and HER receptors occurring at membrane level. Finally, IMO plus trastuzumab produces a cooperative antiangiogenic effect related to suppression of endothelial HER-related signaling. CONCLUSIONS: We showed a cooperative effect of IMO plus trastuzumab in trastuzumab-resistant breast cancers due to IMO direct antitumor and antiangiogenic activity and antibody-dependent cell-mediated cytotoxicity enhancement. Moreover, we provided first evidence of a Toll-like receptor 9/HER interaction at membrane level as novel mechanism of action. Altogether, we propose IMO plus trastuzumab as an effective strategy in trastuzumab-resistant breast cancers.

Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy.

Autophagy. 2010 Jan 13; 6(1):
Yuk JM, Shin DM, Song KS, Lim K, Kim KH, Lee SH, Kim JM, Lee JS, Paik TH, Kim JS, Jo EK

The cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin (BCG/CWS) is an effective antitumor immunotherapy agent. Here, we demonstrate that BCG/CWS has a radiosensitizing effect on colon cancer cells through the induction of autophagic cell death. Exposure of HCT116 colon cancer cells to BCG/CWS before ionizing radiation (IR) resulted in increased cell death in a caspase-independent manner. Treatment with BCG/CWS plus IR resulted in the induction of autophagy in colon cancer cells. Either the autophagy inhibitor 3-methyladenine or knockdown of beclin 1 or Atg7 significantly reduced tumor cell death induced by BCG/CWS plus IR, whereas the caspase inhibitor z-VAD-fmk failed to do so. BCG/CWS plus IR-mediated autophagy and cell death was mediated predominantly by the generation of reactive oxygen species (ROS). The c-Jun NH(2)-terminal kinase pathway functioned upstream of ROS generation in the induction of autophagy and cell death in HCT116 cells after co-treatment with BCG/CWS and IR. Furthermore, Toll-like receptor (TLR) 2, and in part, TLR4, were responsible for BCG/CWS-induced radiosensitization. In vivo studies revealed that BCG/CWS-mediated radiosensitization of HCT116 xenograft growth is accompanied predominantly by autophagy. Our data suggest that BCG/CWS in combination with IR is a promising therapeutic strategy for enhancing radiation therapy in colon cancer cells through the induction of autophagy.

Kinome analysis of Toll-like receptor signaling in bovine monocytes.

J Recept Signal Transduct Res. 2009 Nov 9;
Arsenault RJ, Jalal S, Babiuk LA, Potter A, Griebel PJ, Napper S

The Toll-like receptors (TLRs) are a family of pathogen recognition receptors that alert the host to the presence of microbial challenge. Each TLR responds to a specific microbial associated ligand. For example, TLR4 is activated by lipopolysaccharide (LPS), whereas TLR9 responds to microbial DNA (CpGs). In this report signal transduction responses of bovine monocytes to stimulation with LPS and CpG are described through a bovine-specific peptide array. In addition to confirming activation of the defined TLR pathway in bovine cells, unique phosphorylation events not previously attributed to TLR signaling are described and validated. For example, array data predicts phosphorylation of Tyr40 of Etk in response to LPS, but not CpG, stimulation as well as the activation of oxidative burst in CpG, but not LPS. This investigation confirms interspecies conservation of the TLR pathway in bovine as well as providing insight into the complexity and mechanisms of TLR signaling.

Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines.

Nat Immunol. 2009 Nov 8;
Tseng PH, Matsuzawa A, Zhang W, Mino T, Vignali DA, Karin M

Balanced production of type I interferons and proinflammatory cytokines after engagement of Toll-like receptors (TLRs), which signal through adaptors containing a Toll-interleukin 1 receptor (TIR) domain, such as MyD88 and TRIF, has been proposed to control the pathogenesis of autoimmune disease and tumor responses to inflammation. Here we show that TRAF3, a ubiquitin ligase that interacts with both MyD88 and TRIF, regulated the production of interferon and proinflammatory cytokines in different ways. Degradative ubiquitination of TRAF3 during MyD88-dependent TLR signaling was essential for the activation of mitogen-activated protein kinases (MAPKs) and production of inflammatory cytokines. In contrast, TRIF-dependent signaling triggered noncanonical TRAF3 self-ubiquitination that activated the interferon response. Inhibition of degradative ubiquitination of TRAF3 prevented the expression of all proinflammatory cytokines without affecting the interferon response.

The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation.

PLoS Pathog. 2009 Nov; 5(11): e1000650
Nakhaei P, Mesplede T, Solis M, Sun Q, Zhao T, Yang L, Chuang TH, Ware CF, Lin R, Hiscott J

The primary role of the innate immune response is to limit the spread of infectious pathogens, with activation of Toll-like receptor (TLR) and RIG-like receptor (RLR) pathways resulting in a pro-inflammatory response required to combat infection. Limiting the activation of these signaling pathways is likewise essential to prevent tissue injury in the host. Triad3A is an E3 ubiquitin ligase that interacts with several components of TLR signaling and modulates TLR activity. In the present study, we demonstrate that Triad3A negatively regulates the RIG-I RNA sensing pathway through Lys48-linked, ubiquitin-mediated degradation of the tumor necrosis factor receptor-associated factor 3 (TRAF3) adapter. Triad3A was induced following dsRNA exposure or virus infection and decreased TRAF3 levels in a dose-dependent manner; moreover, Triad3A expression blocked IRF-3 activation by Ser-396 phosphorylation and inhibited the expression of type 1 interferon and antiviral genes. Lys48-linked ubiquitination of TRAF3 by Triad3A increased TRAF3 turnover, whereas reduction of Triad3A expression by stable shRNA expression correlated with an increase in TRAF3 protein expression and enhancement of the antiviral response following VSV or Sendai virus infection. Triad3A and TRAF3 physically interacted together, and TRAF3 residues Y440 and Q442--previously shown to be important for association with the MAVS adapter--were also critical for Triad3A. Point mutation of the TRAF-Interacting-Motif (TIM) of Triad3A abrogated its ability to interact with TRAF3 and modulate RIG-I signaling. TRAF3 appears to undergo sequential ubiquitin "immuno-editing" following virus infection that is crucial for regulation of RIG-I-dependent signaling to the antiviral response. Thus, Triad3A represents a versatile E3 ubiquitin ligase that negatively regulates RIG-like receptor signaling by targeting TRAF3 for degradation following RNA virus infection.

Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: Role of TLR4-dependent NADPH oxidase activation.

Free Radic Biol Med. 2009 Nov 2;
Lin CC, Lee IT, Yang YL, Lee CW, Kou YR, Yang CM

Exposure to cigarette smoke extract (CSE) leads to airway and lung inflammation through oxidant-antioxidant imbalance. Cyclooxygenase-2 (COX-2) and prostaglandin E(2) (PGE(2)) have been demonstrated to play critical roles in respiratory inflammation. Here, we show that COX-2/PGE(2)/IL-6 induction is dependent on Toll-like receptor 4 (TLR4)/NADPH oxidase signaling in human tracheal smooth muscle cells (HTSMCs). CSE induced COX-2 expression in vitro in HTSMCs and in vivo in the airways of mice. CSE also directly caused an increase in TLR4. Moreover, CSE-regulated COX-2, PGE(2), and IL-6 generation were inhibited by pretreatment with TLR4 Ab, the inhibitors of c-Src (PP1), NADPH oxidase (diphenylene iodonium chloride and apocynin), p38 MAPK (SB202190), MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (helenalin), or a ROS scavenger (N-acetyl-L-cysteine) or transfection with siRNA of TLR4, MyD88, TRAF6, Src, p47(phox), p38, p42, JNK2, or p65. CSE-induced leukocyte count in BAL fluid was also reduced by pretreatment with these inhibitors. Furthermore, CSE induced p47(phox) translocation and TLR4/MyD88/TRAF6 and c-Src/p47(phox) complex formation. We found that PGE(2) enhanced IL-6 production in HTSMCs and leukocyte count in BAL fluid. In addition, treatment with nicotine could induce COX-2, PGE(2), and IL-6 generation in in vivo and in vitro studies. These results demonstrated that CSE-induced ROS generation was mediated through the TLR4/MyD88/TRAF6/c-Src/NADPH oxidase pathway, in turn initiated the activation of MAPKs and NF-kappaB, and ultimately induced COX-2/PGE(2)/IL-6-dependent airway inflammation.

Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.

Acta Pharmacol Sin. 2009 Nov; 30(11): 1522-8
Wang W, Xu M, Zhang YY, He B

AIM: To investigate the molecular mechanism and signaling pathway by which fenoterol, a beta(2)-adrenergic receptor (beta(2)-AR) agonist, produces anti-inflammatory effects. METHODS: THP-1, a monocytic cell line, was used to explore the mechanism of beta(2)-AR stimulation in LPS-induced secretion of inflammatory cytokines and changes of Toll-like receptors (TLRs). We labeled TLR4 and CD14 using monoclonal anti-TLR4 PE-conjugated and anti-CD14 FITC-conjugated antibodies in THP-1 cells stimulated by beta(2)-AR in the presence or absence of lipopolysaccharide (LPS) and small, interfering RNA (siRNA)-mediated knockdown of beta-arrestin-2, and then analyzed their changes in distribution by flow cytometry, Western blotting and confocal analysis. RESULTS: LPS-induced membrane-bound CD14, TLR4/CD14 complex levels and elevation of inflammatory cytokines were all significantly reduced by pre-incubation of fenoterol (P<0.05). However, the total level of CD14 and TLR4 was not significantly changed. Interestingly, confocal microscopy revealed redistribution of CD14 and TLR4/CD14 complex under beta(2)-AR stimulation. Furthermore, siRNA-mediated knockdown of beta-arrestin-2 eliminated the anti-inflammatory effects and redistribution of CD14 and TLR4/CD14 complex stimulated by beta(2)-AR. CONCLUSION: beta(2)-AR agonist exerts its anti-inflammatory effects by down-regulating TLR signaling in THP-1 cells, potentially resulting from beta-arrestin-2 mediated redistribution of CD14 and TLR14/CD14 complex.

Up-Regulation of Toll-like receptor 4/Nuclear Factor-{kappa}B signaling Is Associated with Enhanced Adipogenesis and Insulin Resistance in Fetal Skeletal Muscle of Obese Sheep at Late Gestation.

Endocrinology. 2009 Nov 3;
Yan X, Zhu MJ, Xu W, Tong JF, Ford SP, Nathanielsz PW, Du M

Maternal obesity is increasing at an alarming rate. We previously showed that maternal obesity induces an inflammatory response and enhances adipogenesis in fetal skeletal muscle at midgestation. The objective of this study was to evaluate effects of maternal obesity on adipogenesis, inflammatory signaling, and insulin pathways at late gestation when ovine fetal skeletal muscle matures. Nonpregnant ewes were assigned to a control diet (Con, fed 100% of National Research Council nutrient recommendations, n = 6) or obesogenic diet (OB, fed 150% of National Research Council recommendations, n = 6) from 60 d before to 135 d after conception (term 148 d) when the fetal semitendenosus skeletal muscle was sampled. Expression of the adipogenic marker, peroxisome proliferator-activated receptor-gamma, was increased in OB compared with Con fetal semitendenosus muscle, indicating up-regulation of adipogenesis. More intramuscular adipocytes were observed in OB muscle. Phosphorylation of inhibitor-kappaB kinase-alpha/beta and nuclear factor-kappaB RelA/p65 were both increased in OB fetal muscle, indicating activation of nuclear factor-kappaB pathway. Phosphorylation of c-Jun N-terminal kinase and c-Jun (at Ser 63 and Ser 73) was also elevated. Toll-like receptor 4 expression was higher in OB than Con fetal muscle. Moreover, despite higher insulin concentrations in OB vs. Con fetal plasma (2.89 +/- 0.53 vs. 1.06 +/- 0.52 ng/ml; P < 0.05), phosphorylation of protein kinase B at Ser 473 was reduced, indicating insulin resistance. In conclusion, our data show maternal obesity-induced inflammatory signaling in late gestation fetal muscle, which correlates with increased im adipogenesis and insulin resistance, which may predispose offspring to later-life obesity and diabetes.

Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation.

Clin Cancer Res. 2009 Nov 15; 15(22): 6751-7
Martinez-Forero I, Rouzaut A, Palazon A, Dubrot J, Melero I

Covalent and reversible post-translational modifications of proteins are a common theme in signaling. Ubiquitin conjugation was originally described to target proteins to proteasomal degradation by ubiquitin polymerization involving lysine (K) 48 residues. Differently linked polymers of polyubiquitin have been found that modify proteins without targeting to proteasomal degradation. Instead this pathway creates docking sites for signaling scaffolds that are key to control the nuclear factor-kappaB (NF-kappaB) pathway. Indeed TRAF-2, TRAF-6, and TRAF-3 are E3 ubiquitin ligases that form K63-linked ubiquitin polymers. Therefore signaling via TNF family receptors, IL1R, IL-18R, T-cell receptor (TCR), and Toll-like receptors (TLR) use this type of post-translational modification. Specific enzymes exist (DUBs) that deactivate this system, degrading K63 polyubiquitin chains. Interestingly, mice deficient in these deubiquitinases develop autoimmunity and inflammation. In carcinogenesis, the K63 polyubiquitin pathway is possibly critical for inflammation-driven tumor promotion. The pathway is also critically involved in costimulation of tumor immunity/immunotherapy as well as in the biology of malignant cells themselves. The elements of this new signaling paradigm offer the opportunity for therapeutic exploitation and drug discovery.

Mouse mesenchymal stem cells suppress antigen-specific TH-cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1).

Stem Cells Dev. 2009 Nov 3;
Lanz T, Opitz C, Ho P, Agrawal A, Lutz C, Weller M, Mellor A, Steinman L, Wick W, Platten M

Due to their immunosuppressive properties human mesenchymal stem cells (hMSC) represent a promising tool for cell-based therapies of autoimmune diseases such as multiple sclerosis (MS). Mouse MSC (mMSC) have been used extensively to characterize and optimize route of administration, motility, cellular targets and immunosuppressive mechanisms in mouse models of autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE). Tryptophan (trp) catabolism by indolamine-2,3-dioxygenase 1 (IDO1) is a chief endogenous metabolic pathway that tightly regulates unwanted immune responses through depletion of trp and generation of immunosuppressive kynurenines (kyn). IDO1 activity contributes to the immunosuppressive phenotype of hMSC. Here we demonstrate that although IDO1 is inducible in bone marrow-derived mMSC by proinflammatory stimuli such as interferon-gamma (IFN-gamma) and ligands of Toll-like receptors (TLR), it does not lead to catabolism of trp in vitro. This failure to catabolize trp is not due to defective TLR signaling as demonstrated by induction of interleukin 6 (IL-6) by TLR activation. While mMSC suppressed the activation of antigen-specific myelin-oligodendrocyte glycoprotein (MOG)-reactive T cell receptor (TCR) transgenic T helper (TH) cells in coculture, neither pharmacologic inhibition nor genetic ablation of IDO1 reversed this suppressive effect. Finally, systemic administration of both, IDO1-proficient and phenotypically identical IDO1-deficient mMSC equally resulted in amelioration of EAE. mMSC, unlike hMSC, do not display IDO1-mediated suppression of antigen-specific T cell responses.

Inhibition of double-stranded RNA-induced inducible nitric oxide synthase expression by fraxinellone and sauchinone in murine microglia.

Biol Pharm Bull. 2009 Nov; 32(11): 1870-4
Lee CS, Won C, Yoo H, Yi EH, Cho Y, Maeng JW, Sung SH, Ye SK, Chung MH

Fraxinellone and sauchinone, isolated from natural substance, are known to have an anti-inflammatory effect in inflammatory conditions. However, the anti-inflammatory actions of these compounds have been insufficiently demonstrated in viral-induced neuroinflammation. A viral component (double-stranded (ds)RNA) triggers a Toll-like receptor 3-dependent inflammatory response that stimulates pro-inflammatory mediators in the brain. In present study, we initially examined the biological effects of fraxinellone and sauchinone on anti-inflammatory actions in dsRNA-stimulated microglia. Both compounds inhibited dsRNA-induced inducible nitric oxide synthase (iNOS) expression, a major pro-inflammatory enzyme. To demonstrate the mechanism of inhibitory effect on iNOS expression, we further examined the signaling pathway induced by dsRNA in microglia. Our data show that dsRNA promotes the expression of signal transducers and activators of transcription (STAT)1/3 identified as major inflammatory transcription factors as well as activates c-Jun N-terminal kinase (JNK) in an early time. Moreover, both compounds suppressed activation of JNK-STAT1/3 signaling pathway. These results suggest that an anti-inflammatory effect by fraxinellone and sauchinone is mediated via blockade of the JNK-STAT1/3-iNOS signaling pathway in viral-infected microglia.

Adjuvants and autoimmunity.

Lupus. 2009 Nov; 18(13): 1217-25
Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y

Some adjuvants may exert adverse effects upon injection or, on the other hand, may not trigger a full immunological reaction. The mechanisms underlying adjuvant adverse effects are under renewed scrutiny because of the enormous implications for vaccine development. In the search for new and safer adjuvants, several new adjuvants were developed by pharmaceutical companies utilizing new immunological and chemical innovations. The ability of the immune system to recognize molecules that are broadly shared by pathogens is, in part, due to the presence of special immune receptors called Toll-like receptors (TLRs) that are expressed on leukocyte membranes. The very fact that TLR activation leads to adaptive immune responses to foreign entities explains why so many adjuvants used today in vaccinations are developed to mimic TLR ligands. Alongside their supportive role, adjuvants were found to inflict by themselves an illness of autoimmune nature, defined as 'the adjuvant diseases'. The debatable question of silicone as an adjuvant and connective tissue diseases, as well as the Gulf War syndrome and macrophagic myofaciitis which followed multiple injections of aluminium-based vaccines, are presented here. Owing to the adverse effects exerted by adjuvants, there is no doubt that safer adjuvants need to be developed and incorporated into future vaccines. Other needs in light of new vaccine technologies are adjuvants suitable for use with mucosally delivered vaccines, DNA vaccines, cancer and autoimmunity vaccines. In particular, there is demand for safe and non-toxic adjuvants able to stimulate cellular (Th1) immunity. More adjuvants were approved to date besides alum for human vaccines, including MF59 in some viral vaccines, MPL, AS04, AS01B and AS02A against viral and parasitic infections, virosomes for HBV, HPV and HAV, and cholera toxin for cholera. Perhaps future adjuvants occupying other putative receptors will be employed to bypass the TLR signaling pathway completely in order to circumvent common side effects of adjuvant-activated TLRs such as local inflammation and the general malaise felt because of the costly whole-body immune response to antigen.

Toll-like receptors in Pregnancy Disorders and Placental Dysfunction.

Clin Rev Allergy Immunol. 2009 Oct 29;
Riley JK, Nelson DM

The Toll receptor was originally identified as a regulator of embryogenesis in Drosophila. Toll-like receptors (TLRs) in mammals recognize infectious agents and other danger signals. Activation of TLRs on trophoblast influences immune cell recruitment, cytokine secretion, and decidual responses to invading pathogens during pregnancy. Importantly, biological effects of TLR signal transduction at multiple maternal-fetal interfaces may contribute to several pregnancy pathologies associated with placental dysfunction, including pre-eclampsia, intrauterine growth restriction, and preterm labor. We herein discuss mechanisms by which TLRs regulate the maternal immune response during normal and abnormal gestation, and we highlight recent data that assign a role to TLRs in the pathophysiology of selected pregnancy-associated complications.

Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo.

Mucosal Immunol. 2009 Oct 28;
Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, Fasano A, Vogel SN

Toll-like receptors (TLRs) and proteinase-activated receptors (PARs) function as innate immune biosensors in mucosal epithelial cells (ECs). We previously reported the functional and physical interactions between TLR4 and PAR(2). We have extended these findings herein by showing the cooperation between PAR(2) and TLR2, TLR3, or TLR4 for activation of nuclear factor-kappaB-dependent signaling in mucosal EC lines. In contrast, activation of PAR(2) negatively regulated TLR3-dependent antiviral pathway, blunting the expression of TLR3/interferon regulatory factor-3 (IRF-3)-driven genes, as well as activation of IRF-3 and STAT1. Consistent with these in vitro observations, PAR(2)(-/-) and TLR4(-/-) mice, which were refractory to footpad edema induced by PAR(2) agonist peptide, were protected from mouse-adapted H1N1 influenza A virus-induced lethality when compared to wild-type (WT) mice. These data support and extend our recently described, novel model of PAR(2)-TLR4 "receptor cooperativity" and highlight the complexity of signaling integration between heterologous innate immune biosensors.Mucosal Immunology advance online publication 28 October 2009. doi:10.1038/mi.2009.120.

Transcriptional control of the inflammatory response.

Nat Rev Immunol. 2009 Oct; 9(10): 692-703
Medzhitov R, Horng T

Inflammation is a multicomponent response to tissue stress, injury and infection, and a crucial point of its control is at the level of gene transcription. The inducible inflammatory gene expression programme--such as that triggered by Toll-like receptor signalling in macrophages--is comprised of several coordinately regulated sets of genes that encode key functional programmes; these are controlled by three classes of transcription factors, as well as various transcriptional co-regulators and chromatin modifications. Here, we discuss the mechanisms of and the emerging principles in the transcriptional regulation of inflammatory responses in diverse physiological settings.